EPC 2021 Updates in Pulmonary Disease - September

September 30, 2021 to October 3, 2021

Didactic lectures allow the speakers to provide evidence based medical recommendations, updates and expert opinion.
 

Accreditation 
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the American College of Allergy, Asthma & Immunology and the Eastern Pulmonary Conference.  The American College of Allergy, Asthma and Immunology is accredited by the ACCME to provide continuing medical education for physicians.

Designation
The American College of Allergy, Asthma & Immunology (ACAAI) designates this live activity for a maximum of 13.75 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CBRN
The American College of Allergy, Asthma & Immunology (ACAAI) is a provider, approved by the California Board of Registered Nursing, Provider Number CEP17239, for 13.75 contact hours.

Target Audience

Practicing allergists, pulmonologists and allied healthcare professionals in the field of allergy, asthma and immunology.

Learning Objectives

At the conclusion of this activity, participants should be able to:

 

  • Recognize the rationale for the clinical work-up of patients with interstitial lung disease and how the treatment of idiopathic pulmonary fibrosis has been applied to other fibrotic lung diseases
  • Explain the clinical presentations, treatments and outcomes of hypersensitivity pneumonitis and how testing and radiographics can help in the diagnosis.
  • Outline and apply the 2020 NAEPP guidelines for the diagnosis and treatment of asthma and identify the criteria for severe asthma and current and future biologic therapy to control the disease.
  • Recognize the differential diagnosis and workup of patients with eosinophilia and pulmonary infiltrates including eosinophilic granulomatosis with polyangiitis (EGPA)
  • Recognize and manage patients with occupational asthma
  • Discuss and apply the principles for the use of inhaled corticosteroids for the treatment of stages A-D COPD.
  • Recognize how chronic non-invasive positive pressure ventilation can be used in patients with chronic hypercarbic respiratory failure and COPD.
  • Discuss the current molecular approaches to the diagnosis of lung cancers and how novel immunotherapy treatments are applied to these cancers. Recognize how these treatments can result in pulmonary complications and use ASCO guidelines to to manage these events.
  • Explain the clinical presentations, treatments and outcomes of two major non-infectious pneumonias: hypersensitivity pneumonitis and chronic organizing pneumonia.
  • Outline the advances and state of the art approach to pleural infections.
  • Discuss the epidemiology, burden of illness and pathophysiology of obstructive sleep apnea and recognize approaches to challenges in treatment approaches.
  • Explain the recent advances in understanding the pathogenesis of interstitial lung diseases and the advances on treatment in idiopathic pulmonary fibrosis.
  • Recognize the manifestations and approaches to “long haulers” following COVID-19 infection
  • Apply current evidence-based practices to mechanically ventilated critically ill patients and use current guidelines for the management of pain, delirium and agitation in the ICU.
  • Recognize the causes of chronic cough and how to manage these patients
  • Use 2020 Delphi consensus recommendations for a treatment algorithm for pulmonary sarcoidosis
Additional information
Disclosure: 

As required by the Accreditation Council for Continuing Medical Education (ACCME) and in accordance with the American College of Allergy, Asthma and Immunology (ACAAI) policy, all individuals in a position to control or influence the content of an activity must disclose all financial relationships with any ineligible company that have occurred within the past 24 months. The ACCME defines an “ineligible company” as companies whose primary business is producing, marketing, re-selling, or distributing health care goods or services, used by or on patients. Examples of such organizations include:

•    Advertising, marketing, or communication firms whose clients are ineligible companies
•    Bio-medical startups that have begun a governmental regulatory approval process
•    Compounding pharmacies that manufacture proprietary compounds
•    Device manufacturers or distributors
•    Diagnostic labs that sell proprietary products
•    Growers, distributors, manufacturers or sellers of medical foods and dietary supplements
•    Manufacturers of health-related wearable products
•    Pharmaceutical companies or distributors
•    Pharmacy benefit managers
•    Reagent manufacturers or sellers

The ACCME does not consider providers of clinical service directly to patients to be commercial interests. For more information, visit www.accme.org. All identified relevant relationships must be mitigated and the educational content thoroughly vetted for fair balance, scientific objectivity, and appropriateness of patient care recommendations. It is required that disclosure of or absence of relevant financial relationships be provided to the learners prior to the start of the activity.

Learners must also be informed when off-label, experimental/investigational uses of drugs or devices are discussed in an educational activity or included in related materials.

Disclosure in no way implies that the information presented is biased or of lesser quality. It is incumbent upon course participants to be aware of these factors in interpreting the program contents and evaluating recommendations. Moreover, expressed views do not necessarily reflect the opinions of the ACAAI. All identified conflicts of interest have been mitigated.

Course summary
Available credit: 
  • 13.75 AMA PRA Category 1 Credit™
  • 13.75 Attendance
  • 13.75 CBRN
Course opens: 
09/30/2021
Course expires: 
12/31/2023
Event starts: 
09/30/2021 - 4:30pm CDT
Event ends: 
10/03/2021 - 9:30am CDT
Add to calendar: 
Rating: 
0

All identified conflicts of interest have been mitigated.

The individuals listed below disclose the following financial relationships:

Sidney Braman, MD – CME Planner, Speaker
Speaker – Genentech, Merck
Advisor – Boehringer Ingelheim, GSK, Genentech, Merck 

Mario Castro, MD – Speaker
Honorary Grants – NIH, ALA, PCORI, AstraZeneca, GSK, Novartis, Pulmatrix, Sanofi, Shionogi
Speaker – AstraZeneca, GSK, Sanofi, Genentech, TEVA, Regeneron
Consultant – Novartis, Sanofi, Genentech, TEVA
Royalties – Elsevier

Geoffrey Chupp, MD – Speaker 
Advisor – AstraZeneca, Sanofi Genzyme, Genentech, Regeneron, GSK, TEVA, Amgen
Speaker – AstraZeneca, Sanofi Genzyme, Genentech, Regeneron, GSK, TEVA, Amgen
Independent Contractor – AstraZeneca, Sanofi Genzyme, Genentech, Regeneron, GSK, TEVA

William Corrao, MD – CME Planner, Moderator, Speaker
Speaker –GSK, Boehringer Ingelheim

Peter Dicpinigaitis, MD – Speaker
Advisor – Bayer, Bellus, Chiesi, Merck, Shionogi

Marilyn Glassberg, MD – Speaker 
Advisory Board – Boehringer Ingelheim, Roche/Genentech

Anas Hadeh, MD – Speaker
Advisor – GSK, Insmed
Speaker – GSK, Insmed

Jinesh Mehta, MD – Speaker
Speaker – United Therapeutics, Bayer
Lawrence Mohr, Jr., MD – Speaker
Advisor – World Trade Center Health Program
Royalties – Up to Date

Anne O’Donnell, MD – Speaker
Advisor – Insmed, Electromed, Zambon, Boehringer Ingelheim, AstraZeneca
Independent Contractor – Insmed, Zambon, Paratek, Red Hill

Maria Padilla, MD – Speaker
Speaker – France Foundation, Genentech, Vindico Medical Education
Advisor – Boehringer Ingelheim
Independent Contractor – Boehringer Ingelheim

Rey Panettieri Jr., MD – CME Planner, Speaker
Speaker – AstraZeneca, Sanofi, Genentech
Consultant – RIFM
Advisor - AstraZeneca, Genentech, MedImmune, Theravance, Bayer
Independent Contractor – AstraZeneca, RIFM, Novartis, Maven, Optikira, Genentech, Evelobio, 
            Johnson & Johnson 

Charles Powell, MD – Speaker
Independent Contractor – Daiichi Sankyo
Consultant – AstraZeneca, Johnson & Johnson/Ethicon, Bristol Myers Squibb, Senwha Biosciences

Ganesh Raghu, MD – Speaker
Consultant – Boehringer Ingelheim, Roche

Franck Rahaghi, MD – Speaker
Speaker – Mallinckrodt, Bayer
Advisor – Mallinckrodt, Bayer

Russell Settipane, MD – CME Planner, Reviewer
Speaker – ALK, Genentech, Pharming, Regeneron, Shire, Sunovion, Teva, Boehringer Ingelheim
Consultant – Boehringer Ingelheim, RB Health 
Advisory Board – ALK, AstraZeneca, Genentech, Regeneron, Sanofi, Teva, Pharming, GlaxoSmithKline
Independent Contractor – AstraZeneca, Chiesi, Genentech, GlaxoSmithKline, Merck, Novartis, Teva, Syneos Health, BioCryst, Avillon, Regeneron

Momen Wahidi, MD – Speaker
Advisor – Olympus, Pulmonx, Cook, Verathon, Serpex Medical
Speaker – Olympus, Cook

Michael Wechsler, MD – Speaker
Advisor – GSK, AstraZeneca, Sanofi, Regeneron, Novartis, Amgen, Genentech, Equillium, Sentien,  
                 Boehringer Ingelheim

The following have no relevant financial relationships to disclose:
William Greisner III, MD – CME Planner
Katelyn Loiselle, BSN, RN – CME Planner
Ginny Loiselle – Coordinator
David De La Zerda – Speaker 
 

Available Credit

  • 13.75 AMA PRA Category 1 Credit™
  • 13.75 Attendance
  • 13.75 CBRN
Please login or create an account to take this course.